However, in terms of TG, AP severity, and comorbidities, there was no significant difference between the HLAP patients with APOA5 pathogenic mutations and other HLAP patients without APOA5 pathogenic mutations (detailed in Table 3). This evidence concerns the gene APOA5 and alkaline phosphatase measurement.